CClinicalTrials.gg
Sign In
CompletedNCT01436357Updated Nov 19, 2019Results posted

Staged Phase I/II Hepatitis C Prophylactic Vaccine

A Phase 1/2 interventional study of AdCh3NSmut1 and MVA-NSmut in Hepatitis C, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 5 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Prevention

Phase
Phase 1/2
Study type
Interventional
Enrollment
548
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. AdCh3NSmut1 and MVA-NSMut HCV vaccine will be administered to 68 (+/-4) volunteers in stage 1. A planned interim analysis of safety and immunogenicity will be conducted. If no safety signal is detected and there is evidence of a measurable immune response to HCV then 472 (+/-4) volunteers will be enrolled in stage 2. Primary objectives are to 1) assess the safety of AdCh3NSmut1 and MVA-NSmut compared to placebo when administered to HCV-uninfected IDUs and 2) determine if AdCh3NSmut1 and MVA-NSmut HCV vaccines will reduce incidence of chronic HCV infection compared to placebo among HCV-uninfected IDUs. Planned study duration is approx 63 months (accrual time, 2 months vaccination, 18 months follow-up, and 9 months extended observation for subjects becoming viremic in the last month of follow-up).

Read the detailed description

A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. In this clinical trial AdCh3NSmut1 and MVA-NSMut HCV vaccine will be administered intramuscularly to 68 (+/-4) evaluable volunteers in stage 1. A planned interim analysis of safety and immunogenicity will be conducted based on data through 1 week after receipt of the second vaccination. If no safety signal is detected and there is evidence of a measurable immune response to HCV then an additional 472 (+/-4) volunteers will be enrolled in stage 2. The primary objectives of this study will be 1) to assess the safety of the new candidate hepatitis C virus vaccines, AdCh3NSmut1 and MVA-NSmut, compared to placebo when administered to HCV-uninfected injection drug users (IDUs) and 2) to determine if AdCh3NSmut1 and MVA-NSmut HCV vaccines will reduce incidence of chronic HCV infection compared to placebo among HCV-uninfected IDUs. The secondary objective of this study will be to evaluate the immunogenicity of the new candidate hepatitis C virus vaccines, AdCh3NSmut1 and MVA-NSmut, compared to placebo when administered to HCV-uninfected IDUs.The planned duration of the study is approximately 63 months total including accrual time for subjects (assuming 31 months of screening/enrollments, plus 3 months of halted enrollment for the first interim analysis), 2 months vaccination, 18 months follow-up of each enrolled subject, and 9 months extended observation (monthly), from the time of infection, for subjects becoming viremic in the last month of follow-up.

02

Conditions studied

  • Hepatitis C

Keywords

  • AdCh3NSmut1
  • Hepatitis C
  • MVA-NSmut
  • vaccine
03

In context

Hepatitis A

2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.

This study's enrollment of 548 is above the median of 100 across 1,886 interventional studies indexed under Hepatitis A.

Browse Hepatitis A studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,401 studies on the registry; 179 are open to participants now.

Of its 396 completed or terminated interventional studies of FDA-regulated products, 294 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Comprehension of informed consent. - 18-45 year old men or women with acknowledged active IDU in the past 90 days and have no travel plans that would interfere with ability to meet the study visit schedule. - In good general health as determined by a participating study physician and results within acceptable ranges for clinical laboratory evaluations as detailed in Appendix A. - Negative for antibodies to hepatitis C virus (anti-HCV). - Negative for HCV RNA. - Negative antibodies to HIV. - Negative for HBsAg. - Able and willing (in the Investigator's opinion) to comply with all study requirements. - Willing to allow the investigators access to their medical records. - Willingness to practice continuous effective contraception from the screening visit through 90 days after the last vaccination (males and females). - Among females, a negative pregnancy test within 24 hours prior to vaccination. - Agreement to refrain from blood donation during the course of the study or after the study. - Provide written informed consent prior to initiation of any study procedures. - Willing to provide contact information for study follow-up activities, including the address, name and contact information of three people who can be contacted to facilitate follow-up compliance.

Exclusion criteria

Exclusion Criteria:

  • The subject is currently participating in a study that involves an experimental agent (vaccine, drug, biologic device, blood product, or medication) or has received an experimental agent within 30 days prior to enrollment in this study, or expects to receive another experimental agent during participation in this study. - Prior receipt of a recombinant simian or human adenoviral vaccine or MVA vaccine. - Administration of immunoglobulins and/or any blood products within the 90 days preceding the planned administration of the vaccine candidate. - Any confirmed or suspected immunosuppressive or immunodeficient state, including: HIV infection; asplenia; recurrent, severe infections. - History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (i.e., known hypersensitivity to aminoglycosideantibiotics or to egg proteins). - History of clinically significant contact dermatitis or other significant dermatological conditions such as psoriasis. - Any history of anaphylaxis in reaction to vaccination. - Pregnancy, lactation or willingness/intention to become pregnant during the study. - History of cancer (except for successfully treated basal cell carcinoma of the skin and cervical carcinoma in situ). - History of severe psychiatric illness, including severe depression, history of suicidal ideation, suicidal attempts, or psychosis requiring medication. The subject has a diagnosis of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis that is uncontrolled and would interfere with the ability to adhere to the protocol. - Any other serious chronic illness requiring hospital specialist supervision. - Suspected or known current alcohol abuse as defined by a score of 10 or more on the Alcohol Use Disorders Identification Test (AUDIT) C test (a standardized screening tool used to identify hazardous drinkers or those with active alcohol use disorders, including abuse or dependence). - At high risk of HIV infection by the following criteria (adapted from HIV Network for Prevention Trials (HIVNET) behavioral criteria for high risk of HIV): (1) sexually active male who has sex with men (MSM), defined as (i) male who has had anal sex with male sexual partner or partners in the past year or (ii) a male who exchanged sex with male partner(s) for money or drugs in the past year; and (2) female and in a current relationship with a high risk male (active MSM, HIV positive male). - Any other significant disease, disorder or finding, which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, may influence the result of the study, or may influence the subject's ability to participate in the study. - History of or current diagnosis of Diabetes mellitus. - History of or current diagnosis of autoimmune disease. - History of or current cardiac disease including history of myocardial infarction or arrhythmia. - Current diagnosis of active liver disease. - History of seizure disorder or currently taking anti-convulsant therapy that would interfere with safety evaluation. - Uncontrolled hypertension (defined as systolic blood pressure being greater than 140mm Hg or diastolic blood pressure being greater than 90mm Hg). - History of splenectomy. - Long term immunosuppressive use (defined as taken for 14 days or more in total at any time during the past 180 days) of high dose oral or parenteral glucocorticoids (high dose defined as prednisone >/=20 mg total daily dose, or equivalent dose of other glucocorticoids); or high-dose inhaled steroids (high dose defined as >800 mcg/day of beclomethasone dipropionate or equ ivalent); or any use of hepatotoxic or non-FDA approved medication. - Have an acute illness, including an oral temperature greater than or equal to 100.4 degrees Fahrenheit, within 7 days prior to the first vaccination. - Immunization against another pathogen within 14 days of planned injection. Second vaccination exclusion criteria: The following events associated with vaccine immunization constitute absolute contraindications to further administration of vaccine. The subject will not receive additional vaccination, but will continue with scheduled follow-up procedures except vaccination. 1. Anaphylactic reaction following administration of vaccine. 2. Pregnancy. If a woman reports having a positive home urine pregnancy test or a positive in clinic urine pregnancy test prior to a scheduled second vaccination, she is not eligible to receive the study vaccine. If she later returns to clinic and reports having a negative home urine pregnancy test and this is confirmed by a negative in clinic urine pregnancy test and a negative blood pregnancy test she may be eligible for the second vaccination if she is still within the vaccination window and no other exclusion criteria are met. The following adverse events constitute contraindications to administration of vaccine at that point in time. If any one of these adverse events occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date (within 28 days of scheduled administration) or withdrawn at the discretion of the investigator. The subject will not receive additional vaccination, but will continue with all scheduled follow-up procedures except vaccination. 3. Acute disease at the time of vaccination (acute disease is defined as the presence of a moderate or severe illness with or without fever). The vaccine dose can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., temperature of \<38°C (100.4°F). 4. Temperature of >38°C (100.4°F) at the time of vaccination. 5. Immunization against another pathogen within 14 days of vaccination
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
548 participants (actual)

Study arms

  • Experimental
    Arm A (Stage I and II)

    Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10\^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.

    Biological: AdCh3NSmut1 · Biological: MVA-NSmut

  • Placebo comparator
    Arm B (Stage I and II)

    Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.

    Other: Placebo

Interventions

  • BiologicalAdCh3NSmut1

    Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.

  • BiologicalMVA-NSmut

    Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.

  • OtherPlacebo

    Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months

    Chronic hepatitis C virus (HCV) infection was defined by persistent viremia over a period of 6 months after initial detection of primary infection.

    Time frame: 6 months

  2. Number of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After First Vaccination

    Blood was collected at baseline and 1 month after each vaccination for assessment of alanine transferase (ALT) (SGPT), creatinine, hemoglobin, platelets, and white blood cells (WBC). A laboratory AE was defined for ALT as greater than 1.25 times the upper limit of normal. A laboratory AE was defined for creatinine as greater than or equal to 1.2 times the upper limit of normal (as appropriate for age and sex). A laboratory AE was defined for hemoglobin as less that or equal to 12.4 g/dl for males and less than or equal to 10.8 g/dl for females. A laboratory AE was defined for platelets as less than or equal to 117,000 per cumm. A laboratory AE was defined for WBC as less than or equal to 2.9 thou/mcl or greater than or equal to 11.9 thou/mcl.

    Time frame: 1 month after first vaccination

  3. Number of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After Second Vaccination

    Blood was collected at baseline and 1 month after each vaccination for assessment of alanine transferase (ALT) (SGPT), creatinine, hemoglobin, platelets, and white blood cells (WBC). A laboratory AE was defined for ALT as greater than 1.25 times the upper limit of normal. A laboratory AE was defined for creatinine as greater than or equal to 1.2 times the upper limit of normal (as appropriate for age and sex). A laboratory AE was defined for hemoglobin as less that or equal to 12.4 g/dl for males and less than or equal to 10.8 g/dl for females. A laboratory AE was defined for platelets as less than or equal to 117,000 per cumm. A laboratory AE was defined for WBC as less than or equal to 2.9 thou/mcl or greater than or equal to 11.9 thou/mcl.

    Time frame: 1 month after second vaccination

  4. Number of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After First Vaccination

    Participants recorded temperature and the presence and intensity of post-vaccination reactogenicity events daily on an 8-day memory aid. Local solicited reactogenicity events included pain, tenderness, erythema, induration and warmth at the injection site. Systemic solicited reactogenicity events included fever, chills, arthralgia/joint pain, malaise/fatigue, myalgia/body aches, headache, nausea, vomiting, abdominal pain. Severe was defined as "events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually incapacitating." Measured erythema and induration of \>50 mm and oral temperature \>40.0 degrees Celsius were considered severe.

    Time frame: 7 days after first vaccination

  5. Occurrence of Vaccine-related Serious Adverse Events (SAEs) From the Time of First Vaccination Through the Entire Study Period

    The occurrence of SAEs was assessed at every study visit. The occurrence of SAEs may also have come to the attention of the investigator by secondary contacts of the participant when they did not present for study visits. Relationship to vaccine was assessed by the site investigator.

    Time frame: Day 0 to 29 months

  6. Number of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After Second Vaccination

    Participants recorded temperature and the presence and intensity of post-vaccination reactogenicity events daily on an 8-day memory aid. Local solicited reactogenicity events included pain, tenderness, erythema, induration and warmth at the injection site. Systemic solicited reactogenicity events included fever, chills, arthralgia/joint pain, malaise/fatigue, myalgia/body aches, headache, nausea, vomiting, abdominal pain. Severe was defined as "events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually incapacitating." Measured erythema and induration of \>50 mm and oral temperature \>40.0 degrees Celsius were considered severe.

    Time frame: 7 days after second vaccination

Secondary outcomes

  1. Number of Participants With Positive Cell Mediated Immune Response

    Cell mediated immune response was measured by interferon gamma (IFN-gamma) production by T-cells against each of the six HCV genotype 1b peptide pools in the vaccine. Positivity was defined as i) more than 48 spot forming cells per million PBMC; and ii) at least three times the mean background spots per million PBMC found in ELISpot wells containing cells and peptide diluent (DMSO). A participant was considered a responder if a positive response to at least one in 6 mixtures (pools) of peptides was detected.

    Time frame: Within 14 days after the last vaccination (Day 56)

07

Results

Posted Jul 22, 2019

Participant flow

People who are actively injecting drugs who are at high risk for HCV infection, negative for HCV antibodies and HCV RNA at screening, were recruited at 3 clinical sites experienced in recruiting and retaining people who inject drugs in prospective studies. Participants were enrolled between 19MAR2012 and 28OCT2016.

Participant flow — Overall Study
MilestoneAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Started274274
Stage 14948
Stage 2225226
Completed152146
Not completed122128
Withdrew: Death51
Withdrew: Enrolled but not vaccinated11
Withdrew: Incarceration1820
Withdrew: Lost to follow-up6761
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject2638
Withdrew: Physician decision34
Withdrew: Moved out of area12
Withdrew: Subject in rehab01

Outcome measures

PrimaryNumber of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months

Chronic hepatitis C virus (HCV) infection was defined by persistent viremia over a period of 6 months after initial detection of primary infection.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months
ParticipantsAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months1414
Statistical analysis
  • AdCh3NSmut1 and MVA-NSmut vs Sodium Chloride Placebo · Regression, Cox · p = 0.317 · Hazard ratio (hr): 1.529 · 95% CI 0.661 to 3.535
PrimaryNumber of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After First Vaccination

Blood was collected at baseline and 1 month after each vaccination for assessment of alanine transferase (ALT) (SGPT), creatinine, hemoglobin, platelets, and white blood cells (WBC). A laboratory AE was defined for ALT as greater than 1.25 times the upper limit of normal. A laboratory AE was defined for creatinine as greater than or equal to 1.2 times the upper limit of normal (as appropriate for age and sex). A laboratory AE was defined for hemoglobin as less that or equal to 12.4 g/dl for males and less than or equal to 10.8 g/dl for females. A laboratory AE was defined for platelets as less than or equal to 117,000 per cumm. A laboratory AE was defined for WBC as less than or equal to 2.9 thou/mcl or greater than or equal to 11.9 thou/mcl.

Time frame:
1 month after first vaccination
Reported as:
Count of participants · Participants
Number of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After First Vaccination
ParticipantsAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Number of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After First Vaccination7048
Statistical analysis
  • AdCh3NSmut1 and MVA-NSmut vs Sodium Chloride Placebo · Fisher Exact · p = 0.029 · Risk difference (rd): 0.08 · 95% CI -0.01 to 0.16
PrimaryNumber of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After Second Vaccination

Blood was collected at baseline and 1 month after each vaccination for assessment of alanine transferase (ALT) (SGPT), creatinine, hemoglobin, platelets, and white blood cells (WBC). A laboratory AE was defined for ALT as greater than 1.25 times the upper limit of normal. A laboratory AE was defined for creatinine as greater than or equal to 1.2 times the upper limit of normal (as appropriate for age and sex). A laboratory AE was defined for hemoglobin as less that or equal to 12.4 g/dl for males and less than or equal to 10.8 g/dl for females. A laboratory AE was defined for platelets as less than or equal to 117,000 per cumm. A laboratory AE was defined for WBC as less than or equal to 2.9 thou/mcl or greater than or equal to 11.9 thou/mcl.

Time frame:
1 month after second vaccination
Reported as:
Count of participants · Participants
Number of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After Second Vaccination
ParticipantsAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Number of Participants With Clinical Safety Laboratory Adverse Events (AEs) at 1 Month After Second Vaccination7349
Statistical analysis
  • AdCh3NSmut1 and MVA-NSmut vs Sodium Chloride Placebo · Fisher Exact · p = 0.015 · Risk difference (rd): 0.10 · 95% CI 0.01 to 0.20
PrimaryNumber of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After First Vaccination

Participants recorded temperature and the presence and intensity of post-vaccination reactogenicity events daily on an 8-day memory aid. Local solicited reactogenicity events included pain, tenderness, erythema, induration and warmth at the injection site. Systemic solicited reactogenicity events included fever, chills, arthralgia/joint pain, malaise/fatigue, myalgia/body aches, headache, nausea, vomiting, abdominal pain. Severe was defined as "events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually incapacitating." Measured erythema and induration of \>50 mm and oral temperature \>40.0 degrees Celsius were considered severe.

Time frame:
7 days after first vaccination
Reported as:
Count of participants · Participants
Number of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After First Vaccination
ParticipantsAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Number of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After First Vaccination00
Statistical analysis
  • AdCh3NSmut1 and MVA-NSmut vs Sodium Chloride Placebo · Fisher Exact · p = 0.00 · Risk difference (rd): 0.0
PrimaryOccurrence of Vaccine-related Serious Adverse Events (SAEs) From the Time of First Vaccination Through the Entire Study Period

The occurrence of SAEs was assessed at every study visit. The occurrence of SAEs may also have come to the attention of the investigator by secondary contacts of the participant when they did not present for study visits. Relationship to vaccine was assessed by the site investigator.

Time frame:
Day 0 to 29 months
Reported as:
Count of participants · Participants
Occurrence of Vaccine-related Serious Adverse Events (SAEs) From the Time of First Vaccination Through the Entire Study Period
ParticipantsAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Occurrence of Vaccine-related Serious Adverse Events (SAEs) From the Time of First Vaccination Through the Entire Study Period00
PrimaryNumber of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After Second Vaccination

Participants recorded temperature and the presence and intensity of post-vaccination reactogenicity events daily on an 8-day memory aid. Local solicited reactogenicity events included pain, tenderness, erythema, induration and warmth at the injection site. Systemic solicited reactogenicity events included fever, chills, arthralgia/joint pain, malaise/fatigue, myalgia/body aches, headache, nausea, vomiting, abdominal pain. Severe was defined as "events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually incapacitating." Measured erythema and induration of \>50 mm and oral temperature \>40.0 degrees Celsius were considered severe.

Time frame:
7 days after second vaccination
Reported as:
Count of participants · Participants
Number of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After Second Vaccination
ParticipantsAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Number of Participants With Severe Local and/or Systemic Solicited Reactogenicity Signs and Symptoms in the 8 Days (Day 0-7) After Second Vaccination20
Statistical analysis
  • AdCh3NSmut1 and MVA-NSmut vs Sodium Chloride Placebo · Fisher Exact · p = 0.499 · Risk difference (rd): 0.01 · 95% CI -0.08 to 0.10
SecondaryNumber of Participants With Positive Cell Mediated Immune Response

Cell mediated immune response was measured by interferon gamma (IFN-gamma) production by T-cells against each of the six HCV genotype 1b peptide pools in the vaccine. Positivity was defined as i) more than 48 spot forming cells per million PBMC; and ii) at least three times the mean background spots per million PBMC found in ELISpot wells containing cells and peptide diluent (DMSO). A participant was considered a responder if a positive response to at least one in 6 mixtures (pools) of peptides was detected.

Time frame:
Within 14 days after the last vaccination (Day 56)
Reported as:
Count of participants · Participants
Number of Participants With Positive Cell Mediated Immune Response
ParticipantsAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Number of Participants With Positive Cell Mediated Immune Response974

Adverse events

Collected over Solicited reactogenicity symptoms were collected before vaccination, and then daily for 8 days post-vaccination (Day 0-7) after each vaccination on a memory aid. Unsolicited adverse events were collected through Day 90. At visits following Day 90 up to Day 140, only SAE's were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AdCh3NSmut1 and MVA-NSmut5/274 (1.8%)40/274 (14.6%)229/274 (83.6%)
Sodium Chloride Placebo2/272 (0.7%)25/272 (9.2%)172/272 (63.2%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
OverdoseInjury, poisoning and procedural complications5/2740/272
CellulitisInfections and infestations4/2742/272
Psychotic DisorderPsychiatric disorders3/2741/272
PneumoniaInfections and infestations1/2742/272
Suicide AttemptPsychiatric disorders2/2742/272
PancreatitisGastrointestinal disorders2/2740/272
Liver InjuryHepatobiliary disorders2/2740/272
Abscess LimbInfections and infestations2/2740/272
EndocarditisInfections and infestations2/2740/272
Completed SuicidePsychiatric disorders2/2741/272
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAdCh3NSmut1 and MVA-NSmutSodium Chloride Placebo
Injection site painGeneral disorders178/27443/272
Injection site painGeneral disorders140/27421/272
MalaiseGeneral disorders114/27499/272
MyalgiaMusculoskeletal and connective tissue disorders112/27469/272
Injection site erythemaGeneral disorders95/27461/272
HeadacheNervous system disorders95/27464/272
Injection site indurationGeneral disorders79/27429/272
ArthralgiaMusculoskeletal and connective tissue disorders63/27437/272
Injection site warmthGeneral disorders52/27419/272
NauseaGastrointestinal disorders51/27448/272

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AdCh3NSmut1 and MVA-NSmutSodium Chloride PlaceboTotal
<=18 years000
Between 18 and 65 years274274548
>=65 years000
Age, Continuous
Age, Continuous(years)AdCh3NSmut1 and MVA-NSmutSodium Chloride PlaceboTotal
Mean31.3 ± 7.330.4 ± 7.230.9 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)AdCh3NSmut1 and MVA-NSmutSodium Chloride PlaceboTotal
Female6062122
Male214212426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AdCh3NSmut1 and MVA-NSmutSodium Chloride PlaceboTotal
Hispanic or Latino403979
Not Hispanic or Latino234235469
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AdCh3NSmut1 and MVA-NSmutSodium Chloride PlaceboTotal
American Indian or Alaska Native729
Asian246
Native Hawaiian or Other Pacific Islander202
Black or African American6251113
White159175334
More than one race333063
Unknown or Not Reported91221
Region of Enrollment
Region of Enrollment(participants)AdCh3NSmut1 and MVA-NSmutSodium Chloride PlaceboTotal
United States274274548
IL28B Status
IL28B Status(Participants)AdCh3NSmut1 and MVA-NSmutSodium Chloride PlaceboTotal
CC111111222
CT/TT163163326
08

Study locations

5 sites
  • University of California San Francisco - Tenderloin Clinical Research Center
    San Francisco, California 94102-4012, United States
  • UCSF Community Research Center
    San Francisco, California 94102, United States
  • Zuckerberg San Francisco General Hospital Unit 5B
    San Francisco, California 94110, United States
  • Johns Hopkins School of Public Health - Wood Clinic
    Baltimore, Maryland 21205-2400, United States
  • University of New Mexico - Truman Health Services
    Albuquerque, New Mexico 87102, United States
09

References and documents

Publications

  • Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massaccesi G, Osburn WO, Forman M, Thomas E, Thornton K, Wagner K, Vassilev V, Lin L, Lum PJ, Giudice LC, Stein E, Asher A, Chang S, Gorman R, Ghany MG, Liang TJ, Wierzbicki MR, Scarselli E, Nicosia A, Folgori A, Capone S, Cox AL. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. N Engl J Med. 2021 Feb 11;384(6):541-549. doi: 10.1056/NEJMoa2023345. PubMed 33567193 ↗
  • Salinas E, Boisvert M, Upadhyay AA, Bedard N, Nelson SA, Bruneau J, Derdeyn CA, Marcotrigiano J, Evans MJ, Bosinger SE, Shoukry NH, Grakoui A. Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion. J Clin Invest. 2021 Jan 19;131(2):e140590. doi: 10.1172/JCI140590. PubMed 33463551 ↗

Study documents

  • Study protocol · Oct 6, 2015
  • Statistical analysis plan · Jul 30, 2018

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01436357
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Mar 6, 2012
Primary completion
May 25, 2018
Completion
May 25, 2018
Results posted
Jul 22, 2019
Last update
Nov 19, 2019

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hepatitis A→

Other studies from this sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Start the discussion